Evaluation of the effect of P-glycoprotein inhibition and induction on talazoparib disposition in patients with advanced solid tumors.
In vitro data showed that talazoparib is a substrate for P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. This open-label, two-arm, drug-drug interaction Phase 1 study in patients with advanced solid tumors assessed the effect of a P-gp inhibitor (itraconazole) and a P-gp inducer (rifampin) on the pharmacokinetics of a single dose of talazoparib. The safety and tolerability of a single dose of talazoparib with and without itraconazole or rifampin were also assessed. Thirty-six patients were enrolled (Arm A [itraconazole], n = 19; Arm B [rifampin], n = 17). Patients in both arms received two single oral doses of talazoparib (0.5 mg, Arm A; 1 mg, Arm B) alone and with multiple daily oral doses of itraconazole (Arm A) or rifampin (Arm B). Coadministration of itraconazole and talazoparib increased talazoparib AUCinf by ~56% and Cmax by ~40% relative to talazoparib alone. Coadministration of rifampin and talazoparib increased talazoparib Cmax by approximately 37% (GMR 136.6% [90% CI 103.2-180.9]); AUCinf was not affected relative to talazoparib alone (GMR 102.0% [90%CI 94.0-110.7]). Talazoparib had an overall safety profile consistent with that observed in prior studies in which talazoparib was administered as a single dose. Coadministration of itraconazole increased talazoparib plasma exposure compared to talazoparib alone. A reduced talazoparib dose is recommended if coadministration of potent P-gp inhibitors cannot be avoided. Similar exposure was observed when talazoparib was administered alone and with rifampin suggesting that the effect of rifampin on talazoparib exposure is limited.